Tag: anxiety

  • Study finds gender disparity in quality of life for individuals with food allergies

    Study finds gender disparity in quality of life for individuals with food allergies

    [ad_1]

    In a recent systematic review published in Clinical & Experimental Allergy, researchers examined the correlation between health-related quality of life (HRQL) and biological sex among individuals with immunoglobulin E (IgE)-related food allergies and their care providers.

    Study: Associations between gender and health-related quality of life in people with IgE-mediated food allergy and their caregivers: A systematic review. Image Credit: Kaspars Grinvalds/Shutterstock.com
    Study: Associations between gender and health-related quality of life in people with IgE-mediated food allergy and their caregivers: A systematic review. Image Credit: Kaspars Grinvalds/Shutterstock.com

    Background

    Food allergies have a significant impact on individuals and their caregivers, resulting in worse health-related quality of life (HRQL) due to tight dietary restrictions, a lack of treatment alternatives, and the fear of unintentional exposure. Previous studies have reported on the mental well-being and lifestyle implications of food allergy patients and their families but have considered only a subset of patient demographics, specifically gender.

    Understanding the characteristics that influence HRQL is critical for tailored food allergy care, yet there are discrepancies about the role of biological sex on HRQL outcomes among individuals with food allergies. Caregivers, particularly mothers, frequently carry the responsibility of managing food allergy-related anxiety, and mothers are over-represented in food allergy literature, which is most likely owing to gender differences in parenting.

    About the systematic review

    In the present systematic review, researchers examined gender-specific health-related quality of life (HRQL) measurements among food allergy patients, comparing them to those of parents and participants. They also investigated the influence of gender on allergen prevention and treatment.

    The team searched the Embase and Medline databases on April 4, 2022, updating them on December 5, 2023, including records from the APA PsycINFO database. The included studies were interventional or non-interventional studies published in English, reporting original research on the relationship between biological sex and health-associated life quality, as assessed using validated instruments, among individuals with immunoglobulin E-mediated food allergies.

    The team excluded studies evaluating HRQL among individuals with non-IgE-related food allergies and multiple allergies. They also excluded narrative reviews, case studies, gray literature, conference abstracts, opinion pieces, and systematic reviews. Study interventions included educational, medicinal, and psychological types. In cases of undocumented health-associated life quality scores for sex-stratified subgroups, the team extracted p-values denoting HRQL differences in females vs. males.

    Two researchers independently screened titles and abstracts before full-text review to confirm eligibility. The team used the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) to assess study quality and the ROBINS-E tool to conduct sensitivity analyses for non-interventional records. They evaluated bias risks using traffic light plots.

    Results

    Initially, the team identified 4,799 studies, of which 3,927 underwent title-abstract screening, 426 underwent full-text screening, and 34 studies (24 non-interventional and 10 interventional) were analyzed. Researchers used several HRQL instruments in the included studies, of which the age-specific Food Allergy Quality of Life Questionnaire (FAQLQ) was the most frequent, revealing sex-based differences in subdomains associated with emotional impact and dietary risk.

    Female participants with food allergies (63% of studies with pediatric participants, 83% of studies with adult participants) and the maternal parents of individuals with food allergies (50% of caregiver studies) reported poorer health-related quality of life than their male counterparts, irrespective of age, especially in emotional, physical, and food anxiety-associated wellness domains. The team observed sex-based disparities in child health-related quality of life following food allergen immunological therapy. However, selective documentation in the interventional studies indicated that the directional course of the association was unclear.

    Caregiver gender did not impact the proxy-documented health-related quality of life of the study participants, nor did the biological sex of the child affect the caregiver’s health-related quality of life. All studies, except one, received critical to serious bias risk ratings in ROBINS-I evaluations. The most frequent bias sources in the included studies were related to HRQL measurements due to investigators and study participants being aware of interventions and exposure statuses and through inconsistent or inadequate confounding factor considerations. Sensitivity analysis found slight differences in bias risk classifications of poorer quality in four studies of the non-interventional type, as assessed using the ROBINS-E tool, for insufficient consideration of primary bias sources.

    Conclusions

    Overall, the review findings highlighted the impact of gender on HRQL in IgE-related food allergies, with female adults and children reporting lower baseline overall HRQL and mothers experiencing lower subdomain HRQL. The findings emphasize the necessity for personalized allergy treatment techniques and stratifying HRQL outcomes by gender in allergen immunotherapy studies.

    In food allergy investigations, biological sex should be considered a factor influencing participant overall and domain-specific HRQL outcomes. Females with food allergies had lower baseline HRQL total scores than males, with comparable gender disparities across HRQL subdomains.

    The study reveals that an interaction between gender and allergen type may influence HRQL results following therapy. Future studies should concentrate on gender in HRQL to lessen reliance on subgroup and sensitivity analysis.

    [ad_2]

    Source link

  • Study finds digital CBT for children with anxiety delivers on par with traditional methods, lowers costs

    Study finds digital CBT for children with anxiety delivers on par with traditional methods, lowers costs

    [ad_1]

    In a recent study published in The Lancet Psychiatry, a group of researchers evaluated if digitally augmented, therapist-supported, parent-led cognitive behavioral therapy (CBT) is a cost-effective and clinically effective alternative to standard care for treating childhood anxiety.

    Study: Digitally augmented, parent-led CBT versus treatment as usual for child anxiety problems in child mental health services in England and Northern Ireland: a pragmatic, non-inferiority, clinical effectiveness and cost-effectiveness randomised controlled trial. Image Credit: Ground Picture/Shutterstock.comStudy: Digitally augmented, parent-led CBT versus treatment as usual for child anxiety problems in child mental health services in England and Northern Ireland: a pragmatic, non-inferiority, clinical effectiveness and cost-effectiveness randomised controlled trial. Image Credit: Ground Picture/Shutterstock.com

    Background

    Child mental health services worldwide struggle to meet demand, highlighting the need for more accessible care. Digital treatments could significantly expand service capacity, but their full integration into routine care is pending.

    Recognizing the urgency, entities like England’s National Institute for Health and Care Excellence (NICE) emphasize the importance of digital solutions for youth mental health. Anxiety, affecting a significant portion of the population from an early age, leads to major personal and economic impacts.

    CBT, especially in brief, parent-led formats supported by therapists, offers a viable solution by overcoming barriers to access and engaging families directly.

    Digital platforms like the Online Support and Intervention (OSI) for child anxiety, co-developed with families and therapists, show promise in making effective treatments more accessible. However, further research is crucial to evaluate their cost-effectiveness and potential for widespread use in varied clinical contexts.

    About the study 

    The present study was registered and followed a published protocol, sought to involve sites that were part of the National Health Service (NHS) or local authorities, totaling 34 participating sites. These included a diverse mix of NHS Trusts and local authority or voluntary or community sector providers, encompassing 73 Child Mental Health Teams.

    Eligibility criteria for children included being aged 5–12 years with a primary anxiety problem, alongside their parents having sufficient English language proficiency, internet access, and willingness to consent.

    Exclusions applied to children with certain comorbid conditions or those involved in child protection concerns, as well as parents with significant intellectual impairments or severe mental health issues.

    The study acknowledged the unique context of the coronavirus disease 2019 (COVID-19) pandemic, which necessitated a rapid shift to remote service delivery, influencing the trial’s approach to what constituted “treatment as usual.”

    Randomization was carefully managed using a web-based system, ensuring balanced allocation across intervention and control groups, albeit blinding to intervention was not feasible for participants.

    The trial’s procedures were thorough, with families being identified, consented, and assessed online, followed by a structured engagement with the treatment process across both arms.

    Qualitative interviews were conducted to gauge the acceptability of OSI plus therapist support, providing rich insights into participants’ experiences.

    The primary outcome focused on the impact of child anxiety on family life, using the Child Anxiety Impact Scale–Parent Report (CAIS-P), with a comprehensive suite of secondary outcomes to capture a broad spectrum of effects. 

    Study results 

    Between December 5, 2020, and August 3, 2022, 706 families were referred, and out of these referrals, 444 families met the inclusion criteria, provided consent, and were randomized equally between the two study arms.

    Despite initial plans, only 79% of these participants started their allocated treatment within the stipulated 12-week period post-randomization.

    By the end of the trial, completion rates for the 14-week and 26-week assessments were 79% and 74%, respectively, in the OSI plus therapist support and treatment as usual groups.

    The participant demographic was predominantly White-British, with a slight majority of girls over boys and an average child age of 9.20 years. Treatment as usual, primarily consisted of CBT, often delivered through parents.

    Before treatment, parents across both groups had similar expectations regarding the logical nature and potential success of the interventions. However, parents initially felt more confident in the success of the OSI, plus therapist support.

    Post-treatment, therapists felt more comfortable delivering traditional treatment than OSI, expressing hesitancy about future use of OSI, largely due to its novelty and their temporary access during the trial.

    The study found OSI plus therapist support to be non-inferior to traditional treatments across all primary and secondary outcomes, demonstrating minimal differences in effectiveness. This was consistent across various sensitivity analyses.

    Furthermore, there was little difference in utility scores and Quality-Adjusted Life Years (QALYs) between the groups.

    However, the OSI plus therapist support arm showed lower associated costs, primarily due to reduced delivery time. Despite some uncertainty, cost-utility analyses suggested that OSI plus therapist support could be cost-effective under certain scenarios.

    Health economic results revealed minor differences in treatment and resource use outcomes, suggesting the potential cost-effectiveness of OSI plus therapist support, though with noted uncertainty.

    Despite this uncertainty and the absence of serious adverse events, the trial highlighted the feasibility of OSI plus therapist support as an effective and potentially more efficient alternative to traditional treatment methods for child anxiety problems.

    This finding underscores the value of further exploring digitally augmented treatments within child mental health services.

    [ad_2]

    Source link

  • The impact of drinking water quality on mental health and the modifying role of diet

    The impact of drinking water quality on mental health and the modifying role of diet

    [ad_1]

    In a recent study published in BMC Medicine, researchers estimate how exposure to various trace elements in drinking water increases the risk of depression and anxiety.

    Study: Association between drinking water quality and mental health and the modifying role of diet: a prospective cohort study. Image Credit: New Africa / Shutterstock.com

    Background

    Mental health disorders, particularly depression and anxiety, remain a leading cause of both disability and premature death throughout the world. Following the coronavirus disease 2019 (COVID-19) pandemic, the prevalence of both anxiety and depression throughout the world rose by about 25%, thus exemplifying the widespread prevalence of these mental diseases.

    Several factors may increase an individual’s risk of depression or anxiety, including genetics, social environment, and physical environment. Within the physical environment, exposure to heavy metals like cadmium has been shown to increase the risk of depression and anxiety, whereas other elements like manganese, copper, and selenium, all of which combat oxidative stress, have the potential to reduce the risk of depression.

    To date, most studies investigating the impact of environmental risk factors on the incidence of depression and anxiety have been cross-sectional. Within China, few longitudinal studies have examined how exposure to metal and nonmetal elements in drinking water may impact the risk of depression and anxiety.

    About the study

    In the present study, researchers identified people diagnosed with depression and anxiety from the Yinzhou district using International Classification of Disease codes F32 and F41, respectively, in data retrieved from the Yinzhou Health Information System (YHIS). Atomic absorption spectrophotometry (AAS) was used to measure manganese, zinc, copper, iron, aluminum, cadmium, selenium, and fluorine levels in tap water samples collected from 37 sites in the Yinzhou district. 

    Water samples were collected four times each year, with at least one sample collected each season. Exposures were assigned to participants based on their residential addresses and the location of tap water collection sites. Daily exposure to all trace elements in drinking water was calculated and adjusted based on the daily drinking water intake of participants, as well as their age and gender.

    A baseline survey was administered to collect data on participants’ frequency of consuming leafy vegetables, meat, fruits, and fish, with their intake of these dietary components categorized as low, moderate, or high. Data on sociodemographic status, lifestyle, and medical history were also acquired.

    Study findings

    The final analysis included 24,285 individuals between 2016 and 2021 without a history of depression or anxiety. From these individuals, 765 and 1,316 depression and anxiety cases, respectively, were reported during a median follow-up period of 4.72 and 4.68 years, respectively.

    Females, as well as those who never smoked or drank, were more likely to have depression, in addition to a greater risk of hypertension, dyslipidemia, cancer, and stroke. Comparatively, females, less educated individuals, older individuals, never drinkers, non-smokers, and those with a lower income were more likely to have anxiety, diabetes, dyslipidemia, cancer, and stroke, in addition to lower levels of seafood and meat consumption.

    Exposure to aluminum in drinking water was more commonly reported in individuals diagnosed with depression, whereas exposure to manganese, iron, and aluminum in drinking water was higher in individuals with anxiety. Individuals with anxiety were also exposed to lower levels of zinc as compared to healthy participants.

    Long-term exposure to zinc, iron, aluminum, selenium, and fluorine did not impact the risk of depression. Likewise, long-term exposure to zinc, copper, aluminum, cadmium, and fluorine did not increase the risk of anxiety.

    Diet did not have a significant effect on the relationship between the risk of depression and manganese, copper, and cadmium exposure in drinking water. However, the risk of anxiety was greater in individuals who consumed less fruits, more seafood, and meat and who were also exposed to manganese and iron in drinking water. Long-term exposure to copper, selenium, and fluorine was also associated with a greater risk of anxiety in individuals who consumed less leafy vegetables and fruits.

    Lower socioeconomic level was associated with increased exposure to heavy metals, particularly copper, in drinking water. Additionally, older, low-income, and less educated individuals who were exposed to cadmium in drinking water were also at a greater risk of depression.

    Higher education levels were more commonly observed in anxious individuals who were exposed to manganese and selenium in drinking water. Comparatively, exposure to iron in drinking water was also more common in older and less educated individuals with anxiety.

    Conclusions

    The present study findings underscore the need to improve the quality of drinking water and adopt healthy dietary habits to reduce the burden of depression and anxiety, as these measures may contribute to the pathophysiology of depression and anxiety. Public health policies should also address the inequitable effect of exposure to various trace elements in drinking water in relation to the increased risk of mental diseases among people in low socioeconomic strata. 

    Journal reference:

    • Zhou, S., Su, M., Shen, P. et al. (2024). Association between drinking water quality and mental health and the modifying role of diet: a prospective cohort study. BMC Medicine 22(53). doi:10.1186/s12916-024-03269-3

    [ad_2]

    Source link

  • Study reveals high insomnia rates in non-hospitalized COVID-19 survivors

    Study reveals high insomnia rates in non-hospitalized COVID-19 survivors

    [ad_1]

    In a recent study published in Frontiers in Public Health, researchers investigated insomnia prevalence and its association with anxiety and depression in the non-hospitalized coronavirus disease 2019 (COVID-19)-recovered community.

    Study: Sleep quality among non-hospitalized COVID-19 survivors: a national cross-sectional study. Image Credit: Stock-Asso/Shutterstock.com
    Study: Sleep quality among non-hospitalized COVID-19 survivors: a national cross-sectional study. Image Credit: Stock-Asso/Shutterstock.com

    Background

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has afflicted millions globally since late 2019, with most cases resolved by mid-2023. Common symptoms include coughing, weariness, fever, dyspnea, musculoskeletal issues, gastrointestinal complaints, anosmia, dysgeusia, and vertigo. Post-infection and long-term physical and psychological difficulties are serious public health concerns.

    Insomnia is a prevalent complaint, particularly among hospitalized COVID-19 patients. High-risk variables include being female, younger, and more educated, as well as having anxiety, depression, or post-traumatic stress disorder. Poor mental health is associated with insufficient sleep, and chronic disorders such as obstructive sleep apnea (OSA) can affect glycemic control, neurocognitive impairment, and aberrant functional pulmonary alterations.

    About the study

    In the current nationwide cross-sectional study, researchers investigated insomnia prevalence among COVID-19 survivors with no or moderate symptoms who did not require hospitalization throughout the recovery period (six months) and discovered relevant variables.

    Between June and September 2022, the team conducted a web-based survey among 1,056 COVID-19-recovered individuals who recovered within six months of acute SARS-CoV-2 infection and did not need hospitalization. They used the Depression Anxiety and Stress Scale-14 (DASS-14) and the Insomnia Severity Index (ISI). They obtained data on demographics such as age, marital status, sex, educational attainment, occupation, employment status, and comorbidities.

    The team asked the respondents to rate their SARS-CoV-2 infection severity and duration (days from the initial SARS-CoV-2-positive to the initial SARS-CoV-2-negative report). In addition, the respondents compared their sleep quality, sleep initiation, and total sleep duration in the previous two weeks with the time before confirming the SARS-CoV-2 infection.

    The team used multivariate logistic regressions to determine odds ratios (OR) for the relationships between anxiety and depression scores and insomnia levels among the survey respondents. They included adult COVID-19 survivors (who recovered as confirmed using polymerase chain reaction (PCR) within six months and did not require COVID-19-associated hospitalization) in Vietnam’s general population. They excluded individuals diagnosed with insomnia or psychological disorders before the study.

    Results

    The study included 1,056 individuals, with the majority being married (64%), female (69%), and having attended university (69%). After the SARS-CoV-2 infection, almost a third of respondents reported shorter sleep duration, worsened sleep quality, and more difficulties falling asleep, and half of them reported more nocturnal awakenings. Insomnia prevalence was 76%, with 23% of patients reporting severe insomnia.

    Individuals with anxiety (OR, 3.9) or depression (OR, 3.5) had a significantly increased risk of having insomnia. Other characteristics that increased the likelihood of sleeplessness included higher educational attainment and pre-existing medical conditions, but COVID-19 duration and symptoms had no significant relationship.

    Individuals who were divorced or widowed, female, had postgraduate education, were not actively employed, or suffered from chronic medical conditions had higher mean ISI ratings than their peers. Concerning COVID-19, 92% of infected individuals experienced symptoms (mean, 11 weeks). Although these symptomatic individuals showed higher ISI scores (15.2), there was no significant difference compared to individuals without symptoms.

    The mean scores for anxiety and depression were 7.6 and 6.4, respectively, with 439 (42%) and 291 (28%) individuals reporting relevant symptoms, respectively. Individuals with symptoms of anxiety (18.7) and depression (19.1) scored significantly higher on the ISI compared to those without (12.4 and 13.5, respectively). Participants experiencing insomnia scored higher on anxiety (9.2) and depression (7.8) than the overall group mean.

    In univariate analysis, those who were wedded and had a university degree were significantly less likely to experience insomnia than single and formally-educated individuals. Students were significantly more likely to experience insomnia compared to healthcare workers. Individuals with a history of chronic medical conditions were significantly more likely to suffer from insomnia following COVID-19 compared to healthy individuals. After controlling for variables, healthcare professionals had a significantly increased likelihood of insomnia (OR, 1.6) than workers in other professions; however, there were no differences compared to those who did not work or were students.

    Conclusion

    Overall, the study findings highlighted insomnia prevalence among COVID-19 survivors, with more than 75% reporting it. This percentage is much higher than that of the general population (10% to 20%) and hospitalized survivors (12% to 47%). Individuals with chronic medical conditions are more likely to suffer from insomnia, which is underreported. Public health researchers should anticipate a greater frequency of insomnia and sleep disorders in this group, which can last for one-third of healed patients up to one year after infection.

    [ad_2]

    Source link

  • U.S. adults face distress, unequal mental health care access during the COVID-19 era

    U.S. adults face distress, unequal mental health care access during the COVID-19 era

    [ad_1]

    U.S. adults experienced considerable psychological distress and adverse mental health effects as a result of the COVID-19 pandemic according to a study at Columbia University Mailman School of Public Health and Columbia University Irving Medical Center. Based on insurance claims, mental health care provider surveys, and electronic health records the research further revealed a decline in in-person outpatient mental health visits during the acute phase of the pandemic. Findings are reported in the Annals of Internal Medicine.

    The trends and patterns we observed in the United States align with reports globally concluding that several mental health problems, including depression, and generalized anxiety disorder, have become more prevalent during than before the pandemic.”


    Mark Olfson, MD, MPH, Professor of Epidemiology at Columbia Mailman School of Public Health, and Dollard Professor of Psychiatry, Medicine & Law at Columbia University Irving Medical Center 

    To characterize the psychological distress experienced, determine the level of outpatient mental health care, and describe patterns of in-person versus telemental health care, the researchers studied the responses of adults from the Medical Expenditure Panel Surveys by the Agency for Healthcare Research and Quality Component, a nationally representative survey of over 85,000 people. Psychological distress was measured with a 6-point scale range and outpatient mental health care use was determined via computer-assisted personal interviews.

    The rate of serious psychological distress among adults increased from 3.5 percent to 4.2 percent from 2018 to 2021. While outpatient mental health care increased overall as well — from 11.2 percent to 12.4 percent, the rate among adults with serious psychological distress decreased from 46.5 percent to 40.4 percent. Young adults (aged 18 to 44 years significantly increased outpatient mental health care but this pattern was not observed for the middle-aged (aged 45 to 64 years) and older adults (aged >65 years). Similarly, more employed adults reported outpatient mental health treatment care compared to the unemployed. 

    In 2021, 33 percent of mental health outpatients received at least one video visit. The likelihood of receiving in-person, telephone, or video mental health care varied across sociodemographic groups; percentages of video care were higher for younger adults than for middle-aged or older adults, women compared with men, college graduates compared with adults with less education, the seriously distressed, lower-income, unemployed, and rural patients.

    “Thanks to a rapid pivot to telemental health care, there was an overall increase during the pandemic of adults receiving outpatient mental health care in the United States. However, the percentage of adults with serious psychological distress who received outpatient mental health treatment significantly declined. Several groups also had difficulty accessing telemental health care including older individuals and those with lower incomes and less education,” observed Olfson. “These patterns underscore critical challenges to extend the reach and access of telemental health services via easy-to-use and affordable service options.” 

    “Increasing our understanding of the patterns we observed in terms of access to outpatient mental health care including in-person, telephone-administered, and internet-administered outpatient mental health services could inform ongoing public policy discussions and clinical interventions,” noted Olfson. “Identifying low-cost means of connecting lower-income patients to telemental health should be a priority, as well as increasing public investment to make access to high-speed broadband universal.”

    “The national profile of adults who receive outpatient mental health care via telemental health – the younger adult, the employed, higher-income, and privately insured adults, raises concerns about disparities in access to virtual mental health care,” said Olfson. “Unless progress is made in reducing these barriers, primary care clinicians will continue to encounter challenges in connecting their older, unemployed, and lower income patients to video-delivered outpatient mental health care.”

    Co-authors are Chandler McClellan and Samuel H. Zuvekas, Agency for Healthcare Research and Quality; Melanie Wall, Columbia Mailman School of Public Health; and Carlos Blanco, National Institute on Drug Abuse.

    Source:

    Journal reference:

    Olfson, M., et al. (2024). Trends in Psychological Distress and Outpatient Mental Health Care of Adults During the COVID-19 Era. Annals of Internal Medicine. doi.org/10.7326/m23-2824.

    [ad_2]

    Source link

  • Heavy cannabis use linked to increased risk of developing a new anxiety disorder

    Heavy cannabis use linked to increased risk of developing a new anxiety disorder

    [ad_1]

    Twenty-seven percent of individuals who had an emergency department visit for cannabis use developed a new anxiety disorder within three years, according to new research.

    Led by researchers at the Bruyère Research Institute, University of Ottawa Department of Family Medicine, The Ottawa Hospital, and ICES, this is the largest study of the relationship between cannabis use and anxiety to date. The study published today in The Lancet’s open access journal eClinical Medicine included over 12 million individuals living in Ontario, Canada, between 2008 and 2019 who had never received a diagnosis or treatment for anxiety. The researchers used health record data from ICES to compare the risk of developing an anxiety disorder for individuals who had an emergency department (ED) visit for cannabis use compared to the general population.

    Our results suggest that individuals requiring emergency department treatment for cannabis use were both at substantially increased risk of developing a new anxiety disorder and experiencing worsening symptoms for already existing anxiety disorders.”


    Dr. Daniel Myran, Lead Author, Canada Research Chair in Social Accountability at the University of Ottawa, ICES Adjunct Scientist, Investigator at the Bruyère Research Institute, and a Clinician Investigator at The Ottawa Hospital

    Key findings of the study include:

    • Risk of a new anxiety disorder: Within three years, 27.5 percent of individuals who had an ED visit for cannabis use were diagnosed with a new anxiety disorder in an outpatient, ED or hospital setting compared to 5.6 percent of the general population-;a 3.9 fold increased risk after accounting for social factors and other mental health diagnoses. 
    • Risk of severe or worsening anxiety disorders: Within three years, 12.3 percent of individuals who had an ED visit for cannabis use had a hospitalization or an emergency department visit for an anxiety disorder compared to 1.2 percent of the general population-;a 3.7 fold increased risk after accounting for social factors and other mental health diagnoses. 
    • In individuals with an ED visit where cannabis was the main reason for a visit, the risk of having a hospitalization or ED visit for an anxiety disorder increased by 9.4 fold compared to the general population.
    • Men and women and individuals of all ages with an ED visit for cannabis use were at elevated risk of developing new anxiety disorders relative to the general population. Importantly, younger adults (10-24 years) and men were at particularly elevated risk.

    There is an ongoing debate about whether cannabis use causes individuals to develop anxiety disorders or if part of the relationship between cannabis use and anxiety reflects individuals self-medicating anxiety symptoms with cannabis. The current study finds that cannabis use may worsen anxiety and is the largest to date examining this question.

    Regardless of causality, the authors caution against using cannabis to treat symptoms of anxiety given the lack of evidence for its effect, that its use may delay other evidence-based treatments, and the potential risk that it may substantially worsen anxiety symptoms.

    “Cannabis use has rapidly increased in Canada over the past 15 years and there is a general sense that cannabis is relatively harmless or has health benefits. Our study cautions that in some individuals, heavy cannabis use may increase their risk of developing anxiety disorders,” says Dr. Myran.

    Source:

    Journal reference:

    Myran, D. T., et al. (2024) Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study. eClinicalMedicine. doi.org/10.1016/j.eclinm.2024.102455.

    [ad_2]

    Source link

  • Maternal happiness in pregnancy boosts child brain development, study finds

    Maternal happiness in pregnancy boosts child brain development, study finds

    [ad_1]

    A new study in the journal Nature Mental Health explores how a mother’s positive state of mind during pregnancy affects the structure and function of the developing fetal brain by measuring these parameters by 7.5 years of age.

    Study: Maternal positive mental health during pregnancy impacts the hippocampus and functional brain networks in children. Image Credit: Dean Drobot / Shutterstock.com Study: Maternal positive mental health during pregnancy impacts the hippocampus and functional brain networks in children. Image Credit: Dean Drobot / Shutterstock.com

    How does the maternal emotional state affect fetal development?

    During pregnancy, which is a time of significant physical, mental, and social change, anxiety, depression, and other stress-related mental health disorders are frequently reported. These mental health issues have been associated with a durable and adverse effect on fetal brain development.

    For example, previous research has shown that these mental disorders can lead to changes in the growth rate of the fetal hippocampus and a lower density of gray matter in the prefrontal and medial temporal lobes in early childhood. These children may also exhibit altered structure and function of emotion-regulating cortico-limbic networks, which are important for stress management.

    At certain stages, these changes appear to be more significant in girls than boys. Notably, it is not necessary that the mother be clinically anxious or depressed for these alterations to manifest.

    As a key component of mental health, positive maternal emotions like happiness can affect multiple outcomes, including maternal-infant bonding, parenting approaches, and child development. Furthermore, maternal happiness during pregnancy also impacts the long-term health of both the mother and child; however, it remains unclear how positive maternal emotions affect prenatal development.

    About the study

    The current study used data from the Growing Up in Singapore Towards Health Outcomes (GUSTO) cohort. Both structural and functional magnetic resonance imaging (MRI) were performed on children to explore the association of maternal happiness during pregnancy with brain development.

    The researchers developed their own tool to measure positive maternal mental health during pregnancy. This was based on a mental health questionnaire given to pregnant women at 26-28 weeks.

    What did the study show?

    At 7.5 years of age, children are experiencing a vital phase of development during which the brain shifts towards different patterns of activity and cognitive processes develop in new ways. As a result, this period was chosen as the focus of the study.

    Brain areas involved in perceiving and regulating emotions include the hippocampus and amygdala, as well as various functional networks like the visual networks, default mode network (DMN), and functional network. These regions of the brain have also been directly correlated with how the mother cares for the child.

    A composite measure from multiple mental health scales was used for assessing positive maternal emotions during pregnancy. Other potential contributing factors such as socioeconomic status, stress levels, family and friend relationships, and death of close relatives in the two years before and after pregnancy were also recorded to determine a socio-environmental adversity factor. Maternal parenting stress was also assessed when the child was six years of age.

    Interestingly, girls born to mothers who reported feeling happy during pregnancy had larger hippocampus volumes, whereas both boys and girls born to happy mothers exhibited altered functional connectivity of multiple networks.

    When categorized by task-negative and task-positive networks, reduced connectivity between task-negative networks was observed among girls born to mothers with increased positive emotions during pregnancy. Conversely, increased connectivity between task-positive networks was associated with greater maternal happiness during pregnancy.

    Since these findings were absent when explored in relation to depression or anxiety in the mother during pregnancy, the observed changes in functional connectivity may occur specifically with greater maternal positive emotion in pregnancy. This may indicate that maternal happiness transmits to the developing child’s brain through neural changes.

    What are the implications?

    The study findings suggest that feeling happy during pregnancy not only reduces the risk of psychiatric illness in the mother but also potentially acts as a protective factor for fetal brain development.

    Previous studies have shown that anxious and stressed mothers are more likely to have children with hippocampal changes, which may affect the developing brain and lead to impaired stress responses in the future. By encouraging mothers to have positive emotions during pregnancy, hippocampal development in the offspring may be promoted, with better structure and functional networks during the time when children typically begin to attend school.

    Importantly, better hippocampal development is associated with greater childhood resilience, thus serving as an early marker for psychological vulnerability and greater potential for behavioral and emotional problems when encountering stressful circumstances. However, the period of fetal development at which maternal positive emotions occur may modify the impact.

    Future studies are needed to establish and extend these findings, especially to understand the neural basis of prenatal-maternal interactions during psychoneurological development. These studies could support the development of preventive strategies to help mothers feel happy during pregnancy and ultimately promote the mental health of their children.

    Journal reference:

    • Qiu, A., Shen, C., Lopez-Vicente, M., et al. (2024). Maternal positive mental health during pregnancy impacts the hippocampus and functional brain networks in children. Nature Mental Health. doi:10.1038/s44220-024-00202-8.

    [ad_2]

    Source link

  • High maternal cortisol levels linked to unexpected birth problems

    High maternal cortisol levels linked to unexpected birth problems

    [ad_1]

    A snippet of hair can reveal a pregnant person’s stress level and may one day help warn of unexpected birth problems, a study indicates.

    Washington State University researchers measured the stress hormone cortisol in hair samples of 53 women in their third trimester. Of that group, 13 women who had elevated cortisol levels later experienced unpredicted birth complications, such as an early birth or hemorrhaging.

    While more research is needed with larger groups, this preliminary finding could eventually lead to a non-invasive way to identify those at risk for such complications. The researchers reported their findings in the journal Psychoneuroendocrinology.

    There was otherwise nothing about these women that would suggest a disease or anything else complicating the pregnancy. This confirmed some hypotheses that levels of stress, related specifically to cortisol levels, might be associated with adverse birth outcomes.”


    Erica Crespi, a WSU developmental biologist and study’s corresponding author

    As part of the study, the participants all answered survey questions about their levels of psychological distress in addition to having cortisol measurements taken in the third trimester of pregnancy and after they gave birth. The women who experienced unexpected birth complications had elevated cortisol concentrations in their hair, a measure that indicates the stress hormone’s circulating levels in the body during the three months prior to collection. These women also reported feelings of stress, anxiety and depression, but on average, only high cortisol levels during pregnancy showed a strong link to adverse birth outcomes.

    Cortisol, a steroid hormone, rises in humans and many animals to help regulate the body’s response to stress, but prolonged high cortisol is associated with major health problems including high blood pressure and diabetes. Throughout pregnancy, cortisol levels naturally rise two to four times and peak during the third trimester, but the measurements in this study showed even more pronounced elevated cortisol levels among the women who had unexpected birth complications.

    “If this finding holds up, it could be a non-invasive way to get greater insight into who might be at risk because it is information we didn’t get from the survey,” said co-author Sara Waters, a WSU human development researcher. “This was not something we could find out just from asking people about their stress.”

    Two months after giving birth, the group that experienced birth complications continued to show elevated cortisol and gave survey answers indicating continued stress, anxiety and depression. At six months, their cortisol remained elevated, but they started to report lower psychological distress on the survey, which the authors noted might be a sign of recovery.

    Finding ways to reduce stress around birth could help improve outcomes for both infants and mothers, the researchers said. They point out that adverse birth outcomes are rising in the country. The U.S. also notoriously has one of the highest maternal mortality rates among developed countries, with deaths disproportionately impacting Black women and other people of color.

    More needs to be done to improve healthcare and support systems for pregnant people and new parents, Waters said. This study is also a reminder to expectant and new mothers to prioritize their health.

    “It’s very easy to sacrifice our own health and well-being to prioritize our children’s, especially when it feels like resources are scarce,” said Waters. “But our ability to show up as parents comes from a foundation of getting our needs met too – like the saying, ‘you can’t pour from an empty cup.’”

    This study involved an interdisciplinary research team at WSU. In addition to Crespi and Waters, co-authors include first author Jennifer Madigan, a Ph.D. candidate in stress physiology research; Maria Gartstein, a psychology professor; Jennifer Mattera, a psychology Ph.D. student; and Chris Connelly, an associate professor of kinesiology. This research received support from a WSU Grand Challenges Grant as well as interdisciplinary grants from the WSU College of Arts and Sciences, and the WSU Office of Research.

    Source:

    Journal reference:

    Madigan, J. A., et al. (2023). Perinatal hair cortisol concentrations linked to psychological distress and unpredicted birth complications. Psychoneuroendocrinology. doi.org/10.1016/j.psyneuen.2023.106921.

    [ad_2]

    Source link

  • Most stroke survivors can safely take two types of common antidepressants

    Most stroke survivors can safely take two types of common antidepressants

    [ad_1]

    Most stroke survivors were able to safely take two types of common antidepressants, according to a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2024. The meeting will be held in Phoenix, Feb. 7-9, and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.

    Among people with ischemic (clot-caused) stroke, those who began taking an antidepressant known as an SSRI (selective serotonin reuptake inhibitor) and/or an SNRI (serotonin and norepinephrine reuptake inhibitor) for the common conditions of post-stroke depression and anxiety, did not have an increased risk of hemorrhagic (bleeds) stroke or other serious bleeding. This included people taking anticoagulation medications. There was, however, an increased risk of hemorrhagic stroke among stroke patients taking two anti-platelet medications, also called dual anti-platelet therapy or DAPT.

    Mental health conditions, such as depression and anxiety, are very common yet treatable conditions that may develop after a stroke. Our results should reassure clinicians that for most stroke survivors, it is safe to prescribe SSRI and/or SNRI antidepressants early after stroke to treat post-stroke depression and anxiety, which may help optimize their patients’ recovery. However, caution is needed when considering the risk-benefit profile for stroke patients receiving dual anti-platelet therapy because we did find an increased risk of bleeding among this group.”


    Kent P. Simmonds, D.O., Ph.D., study lead author, third-year physical medicine and rehabilitation resident, University of Texas Southwestern Medical Center in Dallas

    According to the American Heart Association’s Heart Disease and Stroke Statistics 2024 Update, when considered separately from other cardiovascular diseases, stroke ranks fifth among all causes of death, behind diseases of the heart, cancer, COVID-19 and unintentional injuries/accidents. Approximately one-third of stroke survivors develop poststroke depression. If left untreated, depression may affect quality of life and reduce the chances for optimal poststroke recovery such as returning to their usual daily living activities without assistance.

    The most common classes of antidepressants are SSRIs or SNRIs, and they are widely used and effective for treating anxiety and depression. However, they may not be prescribed at all or early enough after a stroke, when the risk of depression or anxiety is particularly high, due to concerns that they may increase the risk of a hemorrhagic stroke or other serious types of bleeding.

    Researchers looked at the frequency of serious bleeding among hundreds of thousands of stroke survivors who took different types of SSRI and/or SNRI antidepressants (such as sertraline, fluoxetine, citalopram, venlalfaxine). Serious bleeding was defined as bleeding in the brain, digestive tract; and shock, which occurs when bleeding prevents blood from reaching the body’s tissues.

    Researchers also investigated serious bleeding among stroke survivors who took antidepressants combined with different types of blood-thinning medications that are used to prevent future blood clots. These blood-thinning medications may include either anticoagulants or antiplatelet medications. Anticoagulants are prescribed as a single medication and include medications such as warfarin, apixaban and rivaroxaban. Antiplatelet medications may be prescribed as either a single medication (commonly aspirin) or two types of antiplatelet medications can be used in dual antiplatelet therapy. DAPT includes aspirin plus another antiplatelet medication called a P2Y12 inhibitor (such as clopidogrel, prasugrel or ticagrelor).

    The study found:

    • SSRI and SNRIs were generally safe to start during the important early stages of recovery as patients taking these medications were not more likely to develop serious bleeding compared to stroke survivors who did not take an antidepressant. This included ischemic stroke patients who are also taking anti-coagulation therapy.
    • An increased risk of serious bleeding occurred when SSRIs or SNRIs were taken in combination with DAPT treatments (aspirin and blood thinners). However, the overall risk remained low as serious bleeding events were rare.
    • Among ischemic stroke patients on antidepressant medications, there was a 15% increase in the risk of serious bleeding when taking medications from classes such as mirtazapine, bupropion and tricyclics compared to SSRI/SNRIs.

    “Maximizing rehabilitation early after a stroke is essential because recovery is somewhat time-dependent, and most functional gains occur during the first few months after a stroke,” Simmonds said. “Fortunately, dual antiplatelet therapy is often administered for 14, 30 or 90 days, so, when indicated, clinicians may not need to withhold antidepressant medications for prolonged periods of time. Future research should investigate the risk of bleeding associated with the use of anti-depressant and anxiety medications among patients with hemorrhagic or bleeding stroke.”

    According to a 2022 American Heart Association scientific statement, social isolation and loneliness are associated with about a 30% increased risk of heart attack or stroke, or death from either. “Depression may lead to social isolation, and social isolation may increase the likelihood of experiencing depression. The current study helps answer safety issues around the use of antidepressants for treatment of mental health issues that may develop after a stroke,” said Crystal Wiley Cené, M.D., M.P.H., FAHA, chair of the writing group for the Association’s scientific statement, and a professor of clinical medicine and chief administrative officer for health equity, diversity and inclusion at the University of California San Diego Health. Dr. Cené was not involved in this study.

    Study details and design:

    • The retrospective study included electronic medical records data from 666,150 ischemic stroke patients from over 70 large health care centers in the United States: 35,631 were taking SSRI/SNRI antidepressant medication, and 23,241 were taking other antidepressants; however, most (607,278) were not taking any antidepressant.
    • Patients were treated at 70 health care centers over 20 years.
    • Patients were identified from electronic medical records for 2003 through 2023.

    The study had some limitations. Researchers used statistical methods to adjust for differences among the groups that may not have accounted for all the important differences among the groups. The study also did not account for the dosage, duration, or number of antidepressants taken by participants, which may have affected the results.

    [ad_2]

    Source link

  • Ketamine therapy for mental health a ‘wild West’ for doctors and patients

    Ketamine therapy for mental health a ‘wild West’ for doctors and patients

    [ad_1]

    In late 2022, Sarah Gutilla’s treatment-resistant depression had grown so severe, she was actively contemplating suicide. Raised in foster care, the 34-year-old’s childhood was marked by physical violence, sexual abuse, and drug use, leaving her with life-threatening mental scars.

    Out of desperation, her husband scraped together $600 for the first of six rounds of intravenous ketamine therapy at Ketamine Clinics Los Angeles, which administers the generic anesthetic for off-label uses such as treating depression. When Gutilla got into an Uber for the 75-mile drive to Los Angeles, it was the first time she had left her home in Llano, California, in two years. The results, she said, were instant.

    “The amount of relief I felt after the first treatment was what I think ‘normal’ is supposed to feel like,” she said. “I’ve never felt so OK, and so at peace.”

    For-profit ketamine clinics have proliferated over the past few years, offering infusions for a wide array of mental health issues, including obsessive-compulsive disorder, depression, and anxiety. Although the off-label use of ketamine hydrochloride, a Schedule III drug approved by the FDA as an anesthetic in 1970, was considered radical just a decade ago, now between 500 and 750 ketamine clinics have cropped up across the nation.

    Market researcher Grand View Research pegged industry revenues at $3.1 billion in 2022, and projects them to more than double to $6.9 billion by 2030. Most insurance doesn’t cover ketamine for mental health, so patients must pay out-of-pocket.

    While it’s legal for doctors to prescribe ketamine, the FDA hasn’t approved it for mental health treatment, which means that individual practitioners must develop their own treatment protocols. The result is wide variability among providers, with some favoring gradual, low-dosage treatments while others advocate larger amounts that can induce hallucinations, as the drug is psychedelic at the right doses.

    “Ketamine is the wild West,” said Dustin Robinson, the managing principal of Iter Investments, a venture capital firm specializing in hallucinogenic drug treatments.

    Ketamine practitioners stress that the drug’s emergence as a mental health treatment is driven by a desperate need. Depression is the leading cause of disability in the United States for individuals ages 15-44, according to the National Institute of Mental Health, and around 25% of adults experience a diagnosable mental disorder in any given year.

    Meanwhile, many insurance plans cover mental health services at lower rates than physical health care, despite laws requiring parity. Thus many patients with disorders receive little or no care early on and are desperate by the time they visit a ketamine clinic, said Steven Siegel, chair of psychiatry and the behavioral sciences at the University of Southern California’s Keck School of Medicine.

    But the revelation that “Friends” star Matthew Perry died in part from a large dose of ketamine, along with billionaire Elon Musk’s open use of the drug, has piqued fresh scrutiny of ketamine and its regulatory environment, or lack thereof.

    Commercial ketamine clinics often offer same-day appointments, in which patients can pay out-of-pocket for a drug that renders immediate results. The ketamine is administered intravenously, and patients are often given blankets, headphones, and an eye mask to heighten the dissociative feeling of not being in one’s body. A typical dose of ketamine to treat depression, which is 10 times lower than the dosage used in anesthesia, costs clinics about $1, but clinics charge $600-$1,000 per treatment.

    Ketamine is still shadowed by its reputation as the party drug known as “Special K”; Siegel’s first grant from the National Institutes of Health was to study ketamine as a drug of abuse. It has the potential to send users down a “K hole,” otherwise known as a bad trip, and can induce psychosis. Research in animals and recreational users has shown chronic use of the drug impairs both short- and long-term cognition.

    Perry’s death in October raised alarms when the initial toxicology screening attributed his death to the acute effects of ketamine. A December report revealed Perry received infusion therapy a week before his death but that the fatal blow was a high dose of the substance taken with an opioid and a sedative on the day of his death — indicating that medical ketamine was not to blame.

    A variety of protocols

    Sam Mandel co-founded Ketamine Clinics Los Angeles in 2014 with his father, Steven Mandel, an anesthesiologist with a background in clinical psychology, and Sam said the clinic has established its own protocol. That includes monitoring a patient’s vital signs during treatment and keeping psychiatrists and other mental health practitioners on standby to ensure safety. Initial treatment starts with a low dose and increases as needed.

    While many clinics follow the Mandels’ graduated approach, the dosing protocol at MY Self Wellness, a ketamine clinic in Bonita Springs, Florida, is geared toward triggering a psychedelic episode.

    Christina Thomas, president of MY Self Wellness, said she developed her clinic’s procedures against a list of “what not to do” based on the bad experiences people have reported at other clinics.

    The field isn’t entirely unregulated: State medical and nursing boards oversee physicians and nurses, while the FDA and Drug Enforcement Administration regulate ketamine. But most anesthesiologists don’t have a background in mental health, while psychiatrists don’t know much about anesthesia, Sam Mandel noted. He said a collaborative, multidisciplinary approach is needed to develop standards across the field, particularly because ketamine can affect vital signs such as blood pressure and respiration.

    The protocols governing Spravato, an FDA-approved medication based on a close chemical cousin of ketamine called esketamine, are illustrative. Because it has the potential for serious side effects, it falls under the FDA’s Risk Evaluation and Mitigation Strategies program, which puts extra requirements in place, said Robinson. Spravato’s REMS requires two hours of monitoring after each dose and prohibits patients from driving on treatment days.

    Generic ketamine, by contrast, has no REMS requirements. And because it is generic and cheap, drugmakers have little financial incentive to undertake the costly clinical trials that would be required for FDA approval.

    That leaves it to the patient to assess ketamine providers. Clinics dedicated to intravenous infusions, rather than offering the treatment as an add-on, may be more familiar with the nuances of administering the drug. Ideally, practitioners should have mental health and anesthesia expertise, or have multiple specialties under one roof, and clinics should be equipped with hospital-grade monitoring equipment, Mandel said.

    Siegel, who has researched ketamine since 2003, said the drug is especially useful as an emergency intervention, abating suicidal thoughts for long enough to give traditional treatments, like talk therapy and SSRI antidepressants, time to take effect. “The solutions that we have and have had up until now have failed us,” Mandel said.

    The drug is now popular enough as a mental health treatment that the name of Mandel’s clinic is a daily sight for thousands of Angelenos as it appears on 26 Adopt-A-Highway signs along the 405 and 10 freeways.

    And the psychedelic renaissance in mental health is accelerating. A drug containing MDMA, known as ecstasy or molly, is expected to receive FDA approval in 2024. A drug with psilocybin, the active ingredient in “magic mushrooms,” could launch as early as 2027, the same year a stroke medicine with the active ingredient of DMT, a hallucinogen, is expected to debut.

    Robinson said many ketamine clinics have opened in anticipation of the expanded psychedelic market. Since these new drugs will likely be covered by insurance, Robinson advises clinics to offer FDA-approved treatments such as Spravato so they’ll have the proper insurance infrastructure and staff in place.

    For now, Sarah Gutilla will pay out-of-pocket for ketamine treatments. One year after her first round of infusions, she and her husband are saving for her second. In the meantime, she spends her days on her ranch in Llano where she rescues dogs and horses, and relies on telehealth therapy and psychiatric medications.

    While the infusions aren’t “a magic fix,” they are a tool to help her move in the right direction.

    “There used to be no light at the end of the tunnel,” she said. “Ketamine literally saved my life.”




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link